In last trading session, Inhibikase Therapeutics Inc (NASDAQ:IKT) saw 0.1 million shares changing hands with its beta currently measuring 1.11. Company’s recent per share price level of $3.10 trading at -$0.11 or -3.43% at ring of the bell on the day assigns it a market valuation of $208.30M. That closing price of IKT’s stock is at a discount of -35.48% from its 52-week high price of $4.20 and is indicating a premium of 63.87% from its 52-week low price of $1.12. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.15 million shares which gives us an average trading volume of 662.75K if we extend that period to 3-months.
For Inhibikase Therapeutics Inc (IKT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Inhibikase Therapeutics Inc (NASDAQ:IKT) trade information
Upright in the red during last session for losing -3.43%, in the last five days IKT remained trading in the red while hitting it’s week-highest on Thursday, 01/02/25 when the stock touched $3.10 price level, adding 11.17% to its value on the day. Inhibikase Therapeutics Inc’s shares saw a change of -4.62% in year-to-date performance and have moved -4.62% in past 5-day. Inhibikase Therapeutics Inc (NASDAQ:IKT) showed a performance of -5.49% in past 30-days. Number of shares sold short was 0.19 million shares which calculate 0.17 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6.5 to the stock, which implies a rise of 52.31% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -61.29% in reaching the projected high whereas dropping to the targeted low would mean a loss of -61.29% for stock’s current value.
Inhibikase Therapeutics Inc (IKT) estimates and forecasts
Statistics highlight that Inhibikase Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 136.64% of value to its shares in past 6 months, showing an annual growth rate of 72.83% while that of industry is 16.70. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -23.31% during past 5 years.
Inhibikase Therapeutics Inc (NASDAQ:IKT)’s Major holders
Insiders are in possession of 10.46% of company’s total shares while institution are holding 11.62 percent of that, with stock having share float percentage of 12.98%. Investors also watch the number of corporate investors in a company very closely, which is 11.62% institutions for Inhibikase Therapeutics Inc that are currently holding shares of the company.
